{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:24:36Z","timestamp":1792250676866,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Interv and Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12928-025-01178-7","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T01:57:57Z","timestamp":1753667877000},"page":"36-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Low-density lipoprotein cholesterol to apolipoprotein B ratio as a predictor of clinical outcomes following percutaneous coronary intervention: a propensity score-matched analysis"],"prefix":"10.1007","volume":"41","author":[{"given":"Masaki","family":"Matsuzaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-0566","authenticated-orcid":false,"given":"Takashi","family":"Kuwano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Tsudome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Maruo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Kawahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Shigemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"1178_CR1","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141:e139-596.","journal-title":"Circulation"},{"key":"1178_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12928-024-01022-4","volume":"39","author":"Y Saito","year":"2024","unstructured":"Saito Y, Tsujita K, Kobayashi Y. No standard modifiable cardiovascular risk factors in acute myocardial infarction: prevalence, pathophysiology, and prognosis. Cardiovasc Interv Ther. 2024;39:403\u201311.","journal-title":"Cardiovasc Interv Ther"},{"key":"1178_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s12928-024-01036-y","volume":"39","author":"Y Ozaki","year":"2024","unstructured":"Ozaki Y, Tobe A, Onuma Y, Kobayashi Y, Amano T, Muramatsu T, et al. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2024. Cardiovasc Interv Ther. 2024;39:335\u201375.","journal-title":"Cardiovasc Interv Ther"},{"key":"1178_CR4","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0140-6736(21)00249-X","volume":"397","author":"D Erlinge","year":"2021","unstructured":"Erlinge D, Maehara A, Ben-Yehuda O, B\u00f8tker HE, Maeng M, Kj\u00f8ller-Hansen L, et al. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. Lancet. 2021;397:985\u201395.","journal-title":"Lancet"},{"key":"1178_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12928-024-00994-7","volume":"39","author":"Y Minami","year":"2024","unstructured":"Minami Y, Ako J, Tsujita K, Yokoi H, Ikari Y, Morino Y, et al. Drug intervention as an emerging concept for secondary prevention in patients with coronary disease. Cardiovasc Interv Ther. 2024;39:223\u201333.","journal-title":"Cardiovasc Interv Ther"},{"key":"1178_CR6","first-page":"939","volume":"11","author":"KA Krychtiuk","year":"2022","unstructured":"Krychtiuk KA, Ahrens I, Drexel H, Halvorsen S, Hassager C, Huber K, et al. Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Acute Cardiovasc Care. 2022;11:939\u201349.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"1178_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.931931","volume":"13","author":"Y-N Qiao","year":"2022","unstructured":"Qiao Y-N, Zou Y-L, Guo S-D. Low-density lipoprotein particles in atherosclerosis. Front Physiol. 2022;13: 931931.","journal-title":"Front Physiol"},{"key":"1178_CR8","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1161\/CIRCULATIONAHA.118.034942","volume":"138","author":"E Sliz","year":"2018","unstructured":"Sliz E, Kettunen J, Holmes M, Williams C, Boachie C, Wang Q, et al. Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment. Circulation. 2018;138:2499\u2013512.","journal-title":"Circulation"},{"key":"1178_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5551\/jat.12.67","volume":"12","author":"T Hirano","year":"2005","unstructured":"Hirano T, Ito Y, Yoshino G. Measurement of small dense low-density lipoprotein particles. J Atheroscler Thromb. 2005;12:67\u201372.","journal-title":"J Atheroscler Thromb"},{"key":"1178_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/01.ATV.0000154144.73236.f4","volume":"25","author":"AC St-Pierre","year":"2005","unstructured":"St-Pierre AC, Cantin B, Dagenais GR, Mauri\u00e8ge P, Bernard P-M, Despr\u00e9s J-P, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Qu\u00e9bec Cardiovascular Study: 13-year follow-up data from the Qu\u00e9bec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005;25:553\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1178_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108858","volume":"176","author":"A Viktorinova","year":"2021","unstructured":"Viktorinova A, Malickova D, Svitekova K, Choudhury S, Krizko M. Low-density lipoprotein cholesterol-to-apolipoprotein B ratio as a potential indicator of LDL particle size and plasma atherogenicity in type 2 diabetes. Diabetes Res Clin Pract. 2021;176: 108858.","journal-title":"Diabetes Res Clin Pract"},{"key":"1178_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.5551\/jat.14936","volume":"20","author":"H Arai","year":"2013","unstructured":"Arai H, Kokubo Y, Watanabe M, Sawamura T, Ito Y, Minagawa A, et al. Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita study. J Atheroscler Thromb. 2013;20:195\u2013203.","journal-title":"J Atheroscler Thromb"},{"key":"1178_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032596","volume":"102","author":"HW Jung","year":"2023","unstructured":"Jung HW, Ra M, Bae HJ, Hong S-P. The LDL-C\/Apo B predicts coronary atherosclerotic heart disease in non-diabetic patients without high LDL-C. Medicine (Baltimore). 2023;102: e32596.","journal-title":"Medicine (Baltimore)"},{"key":"1178_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2021.05.010","volume":"329","author":"H Drexel","year":"2021","unstructured":"Drexel H, Larcher B, Mader A, Vonbank A, Heinzle CF, Moser B, et al. The LDL-C\/ApoB ratio predicts major cardiovascular events in patients with established atherosclerotic cardiovascular disease. Atherosclerosis. 2021;329:44\u20139.","journal-title":"Atherosclerosis"},{"key":"1178_CR15","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.numecd.2021.01.013","volume":"31","author":"S Rabizadeh","year":"2021","unstructured":"Rabizadeh S, Rajab A, Mechanick JI, Moosaie F, Rahimi Y, Nakhjavani M, et al. LDL\/apo B ratio predict coronary heart disease in type 2 diabetes independent of ASCVD risk score: a case-cohort study. Nutr Metab Cardiovasc Dis. 2021;31:1477\u201385.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1178_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12933-017-0606-7","volume":"16","author":"S Tani","year":"2017","unstructured":"Tani S, Yagi T, Atsumi W, Kawauchi K, Matsuo R, Hirayama A. Relation between low-density lipoprotein cholesterol\/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol. 2017;16:123.","journal-title":"Cardiovasc Diabetol"},{"key":"1178_CR17","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1253\/circj.CJ-12-1401","volume":"77","author":"S Tani","year":"2013","unstructured":"Tani S, Nagao K, Matsumoto M, Hirayama A. Highly purified eicosapentaenoic acid may increase low-density lipoprotein particle size by improving triglyceride metabolism in patients with hypertriglyceridemia. Circ J. 2013;77:2349\u201357.","journal-title":"Circ J"},{"key":"1178_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/biomedicines10040829","volume":"10","author":"H Superko","year":"2022","unstructured":"Superko H, Garrett B. Small dense LDL: scientific background, clinical relevance, and recent evidence still a risk even with \u201cnormal\u201d LDL-C levels. Biomedicines. 2022;10:829.","journal-title":"Biomedicines"},{"key":"1178_CR19","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.5551\/jat.63229","volume":"29","author":"J Ishii","year":"2022","unstructured":"Ishii J, Kashiwabara K, Ozaki Y, Takahashi H, Kitagawa F, Nishimura H, et al. Small dense low-density lipoprotein cholesterol and cardiovascular risk in statin-treated patients with Coronary Artery Disease. J Atheroscler Thromb. 2022;29:1458\u201374.","journal-title":"J Atheroscler Thromb"},{"key":"1178_CR20","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1373\/clinchem.2009.137489","volume":"56","author":"M Ai","year":"2010","unstructured":"Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, et al. Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem. 2010;56:967\u201376.","journal-title":"Clin Chem"},{"key":"1178_CR21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.5551\/jat.64369","volume":"31","author":"M Inyaku","year":"2024","unstructured":"Inyaku M, Tanaka M, Sato T, Endo K, Mori K, Hosaka I, et al. Calculated small dense low-density lipoprotein cholesterol level is A predominant predictor for new onset of ischemic heart disease. J Atheroscler Thromb. 2024;31:232\u201348.","journal-title":"J Atheroscler Thromb"},{"key":"1178_CR22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.5551\/jat.60954","volume":"29","author":"N Akutsu","year":"2022","unstructured":"Akutsu N, Hori K, Mizobuchi S, Ogaku A, Koyama Y, Fujito H, et al. Clinical importance of the LDL-C\/apolipoprotein B ratio for neointimal formation after everolimus-eluting stent implantations. J Atheroscler Thromb. 2022;29:536\u201350.","journal-title":"J Atheroscler Thromb"},{"key":"1178_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12944-020-01250-6","volume":"19","author":"S Talebi","year":"2020","unstructured":"Talebi S, Bagherniya M, Atkin SL, Askari G, Orafai HM, Sahebkar A. The beneficial effects of nutraceuticals and natural products on small dense LDL levels, LDL particle number and LDL particle size: a clinical review. Lipids Health Dis. 2020;19:66.","journal-title":"Lipids Health Dis"},{"key":"1178_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/MOL.0b013e32833b7756","volume":"21","author":"RM Krauss","year":"2010","unstructured":"Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol. 2010;21:305\u201311.","journal-title":"Curr Opin Lipidol"},{"key":"1178_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0002-9149(02)02427-X","volume":"90","author":"RS Rosenson","year":"2002","unstructured":"Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol. 2002;90:89\u201394.","journal-title":"Am J Cardiol"},{"key":"1178_CR26","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1161\/01.CIR.0000057982.50167.6E","volume":"107","author":"J Vakkilainen","year":"2003","unstructured":"Vakkilainen J, Steiner G, Ansquer J-C, Aubin F, Rattier S, Foucher C, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS): the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation. 2003;107:1733\u20137.","journal-title":"Circulation"},{"key":"1178_CR27","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijcard.2005.02.035","volume":"107","author":"M Rizzo","year":"2006","unstructured":"Rizzo M, Berneis K. Should we measure routinely the LDL peak particle size? Int J Cardiol. 2006;107:166\u201370.","journal-title":"Int J Cardiol"},{"key":"1178_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/MOL.0000000000000963","volume":"36","author":"J Hernando-Redondo","year":"2025","unstructured":"Hernando-Redondo J, Ni\u00f1o OC, Fit\u00f3 M. Atherogenic low-density lipoprotein and cardiovascular risk. Curr Opin Lipidol. 2025;36:8\u201313.","journal-title":"Curr Opin Lipidol"},{"key":"1178_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf207","author":"J Morze","year":"2025","unstructured":"Morze J, Melloni GEM, Wittenbecher C, Ala-Korpela M, Rynkiewicz A, Guasch-Ferr\u00e9 M, et al. ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf207.","journal-title":"Eur Heart J"}],"container-title":["Cardiovascular Intervention and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-025-01178-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12928-025-01178-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-025-01178-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:23:29Z","timestamp":1767885809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12928-025-01178-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1178"],"URL":"https:\/\/doi.org\/10.1007\/s12928-025-01178-7","relation":{},"ISSN":["1868-4300","1868-4297"],"issn-type":[{"value":"1868-4300","type":"print"},{"value":"1868-4297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"7 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}